Heart FailureCVD-PHPTNCT07870369
Cardiovascular Risk in Patients With Primary Hyperparathyroidism
An observational study of Heart Failure and Atrial Fibrillation (AF), run by Medical University of Sofia at 1 site in Bulgaria.
Trial summary
Patients with primary hyperparathyroidism versus healthy controls assessed for their cardiovascular risk and overt CVD Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Heart Failure, Atrial Fibrillation (AF), Arrhythmia
- How many people
- 77 participants
- Where
- 1 siteBulgaria
- Study dates
- 1 Jan 2023to 31 Dec 2025
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: 54 patients with PHPT and 23 controls
Who may be able to join
- confirmed primary hyperparathyroidism
Who cannot join
- secondary hyperparathyroidism
Trial locations and contacts
1 site in 1 country.
About this study
Patients with primary hyperparathyroidism versus healthy controls assessed for their cardiovascular risk and overt CVD
Read the detailed description
A cross-sectional, non-interventional single-center study includding 54 patients with primary hyperparathyroidism and 23 healthy controls. The participants have been examined clinically and with certain instrumental investigations: laboratorys, ECG, Holter ECG echocardiography. We have evaluated comparatively the cardiovascular risk and the over cardiac events in both groups and sought for determinants of cardiaovascular complications in primary hyperparathyoridism.
- Conditions
- Heart Failure, Atrial Fibrillation (AF), Arrhythmia, Coronary Artery Disease, Hypertension (HTN)
- Keywords
- primary hyperparathyoidism, cardiovascular, risk, arrhythmias, hypertension, heart failure
- Medical subject headings
- Heart Failure, Atrial Fibrillation, Arrhythmias, Cardiac, Coronary Artery Disease, Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Primary hyperparathyroidism | Patients with primary hyoerparathyroidism | |
| Control group | Patients withthout primary pyperparathyroidism mateched for age and sex |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cardiovascular events
Any cardiac events
Measured: 24 months
Cardiovascular complications
Any cardiovascular disease
Measured: january 1st 2023 - december 31st 2025
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Oct 2026
- Study start1 Jan 2023
- Primary completion31 Dec 2025
- Study completion31 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Heart FailureStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 77 participants (actual)
Sponsor and investigators
- Lead sponsor
- Medical University of Sofia
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Stefan Naydenov Naydenov, Medical University of Sofia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07870369
- Sponsor's protocol ID
- PHPT-CVD-2023
- Acronym
- CVD-PHPT
- Status last verified
- Oct 2026
- First submitted
- 6 Oct 2026
- Last updated
- 13 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes